Project Grant R21AI186057
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$228K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Manhattan, KS 66506, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,000.00 to the Regents of the University of Minnesota to define the mechanisms by which macrophages restrict the bacterium Klebsiella pneumoniae (KP) during bloodstream infections (bacteremia). The research aims to 1) understand how splenic macrophages restrict KP during bacteremia, 2) elucidate host pathways of KP...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $479,249 to Washington University to conduct research on the molecular mechanisms regulating neutrophil proinflammatory activity in sepsis. The research aims to understand how neutrophil A20 signaling contributes to organ damage in sepsis, utilizing biochemical, cell biological, and intravital imaging...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $383,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Nebraska Medical Center (UNMC) to discover novel antimicrobial peptides that can effectively eliminate drug-resistant gram-negative bacteria. The project aims to elucidate the structure-activity relationship, toxicity, pharmacokinetics, and in vivo efficacy of a novel antimicrobial peptide called Verine...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop new antimicrobial agents and combination therapies to combat the growing threat of Gram-negative bacterial pathogens, specifically carbapenem-resistant Acinetobacter baumannii (CRAB) and Klebsiella pneumoniae (CRKP). The $2,308,174 award, with a performance period from August 2024 to May 2029, will fund three...
The federal Project Grant award R21AI190454 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois. The $456,911 award, effective July 1, 2025 through June 30, 2027, supports research to develop innovative antibiotic combination therapies for treating hypervirulent, multidrug-resistant Klebsiella pneumoniae infections. Key objectives include elucidating the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $3,204,624.00 to the University of Pennsylvania to define the molecular and cellular mechanisms of non-canonical inflammasome responses to lipopolysaccharide (LPS) in mice and humans. The goal is to provide essential insight for developing improved therapeutics to reduce human sepsis and enhance immune responses to...
The University of North Carolina at Chapel Hill was awarded a $427,625 Project Grant by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to study the factors contributing to treatment failure of hypervirulent Klebsiella pneumoniae liver abscesses. The research aims to: 1) use quantitative and imaging mass spectrometry to visualize antibiotic distribution and the role of antibiotic-tolerant cells in treatment failure, and 2) employ...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $413,542 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Charlotte. The 2-year grant, effective August 1, 2025, will fund research to develop a novel nanoparticle-based therapeutic approach for targeting glial cells in the central nervous system. The goal is to limit both intracellular bacterial burden and glia-driven neuroinflammation during...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research provides $259,461 to The Methodist Hospital Research Institute to investigate the genomic factors and clinical impact associated with non-carbapenemase producing carbapenem-resistant Klebsiella pneumoniae (NCP-KPN) infections. The key objectives are to characterize a large international collection of NCP-KPN isolates using whole genome...
The National Institute of General Medical Sciences (NIGMS) awarded a $660,050 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to the University of Miami to study the role of Langerhans cells and their interaction with sensory neurons in wound healing, itch, and pain following burn injuries. The project aims to advance the understanding of molecular mechanisms regulating these processes and explore innovative approaches to treat these conditions by targeting distinct...